Frequently Asked Questions
Common questions about our technology and business model.
What is NuclearMediX?
NuclearMediX is a UK-based radiopharmaceutical biotech developing scalable PET diagnostics and theranostics for precision oncology, built on an 18F-first, click chemistry platform and cassette-enabled manufacturing.
What does platform-driven pipeline mean?
It means we use repeatable design rules: validated biology, modular chemistry, isotope flexibility, and manufacturing-ready synthesis to generate multiple programmes.
Why focus on fluorine-18?
18F enables broader distribution reach and efficient dose production compared to generator-based isotopes, supporting scalable clinical access and high-quality PET imaging.
What is NMX-001A (FETO)?
NMX-001A is an 18F-labelled somatostatin receptor-targeted PET radiotracer designed to image SSTR-expressing tumours, initially focused on neuroendocrine tumours.
Do you develop therapeutic radiopharmaceuticals?
Yes. Our modular design supports diagnostic-to-therapy evolution, enabling theranostic pairing with therapeutic radionuclides as programmes mature.
How do you manufacture and supply products?
We design chemistry for cassette-enabled synthesis and work with hospital and contract radiopharmacies for GMP production and distribution under regulated routes in target markets.
Are you a services company?
No. We are a product-led biotech. We collaborate with partners where it accelerates clinical translation, manufacturing scale, or regional access.
How can we partner with NuclearMediX?
Contact us with your collaboration type: clinical, manufacturing, business development/licensing, or investment. We can explore joint development, manufacturing partnerships, or regional licensing.